|
gptkbp:instanceOf
|
gptkb:drug
Bruton tyrosine kinase inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
2017
|
|
gptkbp:ATCCode
|
L01EL04
|
|
gptkbp:brand
|
gptkb:Calquence
|
|
gptkbp:CASNumber
|
1420477-60-6
|
|
gptkbp:chemicalFormula
|
C26H23N7O2
|
|
gptkbp:contraindication
|
hypersensitivity
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:halfLife
|
1-2 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
acalabrutinib
|
|
gptkbp:KEGGID
|
gptkb:D10841
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:MeSH_ID
|
gptkb:C000627982
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
465.51 g/mol
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3183531
gptkb:DB11703
90458926
|
|
gptkbp:sideEffect
|
gptkb:anemia
diarrhea
fatigue
headache
muscle pain
thrombocytopenia
|
|
gptkbp:target
|
gptkb:Bruton_tyrosine_kinase
|
|
gptkbp:UNII
|
QZV7L4B6F9
|
|
gptkbp:usedFor
|
gptkb:mantle_cell_lymphoma
gptkb:small_lymphocytic_lymphoma
chronic lymphocytic leukemia
|
|
gptkbp:bfsParent
|
gptkb:Calquence
|
|
gptkbp:bfsLayer
|
6
|